- Tiziana Life Sciences said a recently published study provided clinical evidence for the use of a treatment in the prevention of type-one diabetes.

The study was published in the New England Journal of Medicine and focused on the abilities of anti-CD3 antibody, Teplizumab.

Tiziana's own Foralumab offers potential safety and efficacy advantages over other anti-CD3 mAb's because it is the only fully human anti-CD3 mAb, as compared to mouse derived anti-CD3s which have been shown to cause immune reactions in humans, the company said.

Foralumab was currently in a Phase 1 trial at the Harvard Medical School in healthy volunteers to study safety, tolerability and biomarkers of neurodegenerative disease through nasal delivery.

An upcoming Phase 1 trial will evaluate oral Foralumab's safety, tolerability and biomarkers in Crohn's disease and NASH.

A Phase 2 trial in Crohn's and NASH is expected to commence next year.

At 9:59am: [LON:TILS] Tiziana Life Sciences Plc share price was +6p at 69p

Story provided by